Cantor Fitzgerald downgraded Zealand Pharma (ZLDPF) to Neutral from Overweight. Zealand Pharma announced Phase 2b obesity data for petrelintide that showed weight loss of 9% placebo-adjusted at 42 weeks looks similar to cagrilintide and meaningfully below Lilly’s (LLY) eloralintide, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma downgraded to Neutral from Overweight at Cantor Fitzgerald
- Zealand Pharma downgraded to Hold from Buy at SEB Equities
- Zealand Pharma downgraded to Hold from Buy at Nordea
- Zealand Pharma Earnings Call Signals High‑Stakes Expansion
- Zealand Pharma announces topline results from ZP9830 trial